Compare · MYO vs STE
MYO vs STE
Side-by-side comparison of Myomo Inc. (MYO) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYO and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.31B, about 341.3x MYO ($59.5M).
- Over the past year, MYO is down 45.5% and STE is down 13.6% - STE leads by 32.0 points.
- STE has been more active in the news (39 items in the past 4 weeks vs 11 for MYO).
- STE has more recent analyst coverage (16 ratings vs 3 for MYO).
- Company
- Myomo Inc.
- STERIS plc (Ireland)
- Price
- $1.56+18.18%
- $207.96-2.25%
- Market cap
- $59.5M
- $20.31B
- 1M return
- +88.38%
- +3.10%
- 1Y return
- -45.55%
- -13.59%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2017
- News (4w)
- 11
- 39
- Recent ratings
- 3
- 16
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest MYO
- Chief Commercial Officer Mitchell Micah covered exercise/tax liability with 6,529 shares, decreasing direct ownership by 6% to 102,949 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry covered exercise/tax liability with 7,635 shares, decreasing direct ownership by 7% to 100,983 units (SEC Form 4)
- Chief Financial Officer Henry David A covered exercise/tax liability with 10,050 shares, decreasing direct ownership by 2% to 435,124 units (SEC Form 4)
- Director Kirk Thomas F bought $50,803 worth of shares (40,002 units at $1.27), increasing direct ownership by 6% to 693,865 units (SEC Form 4)
- Amendment: Chief Commercial Officer Mitchell Micah sold $77,689 worth of shares (90,231 units at $0.86), decreasing direct ownership by 45% to 109,478 units (SEC Form 4)
- Director Kirk Thomas F bought $24,825 worth of shares (25,000 units at $0.99), increasing direct ownership by 4% to 653,863 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry sold $32,239 worth of shares (32,000 units at $1.01), decreasing direct ownership by 23% to 108,618 units (SEC Form 4)
- SEC Form SD filed by Myomo Inc.
- Director Kirk Thomas F bought $68,243 worth of shares (75,006 units at $0.91), increasing direct ownership by 14% to 628,863 units (SEC Form 4)
- Director Manko Joseph M. Jr. bought $173,908 worth of MYO (201,197 units at $0.86) (SEC Form 4)
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 90 units of Ordinary Shares, decreasing direct ownership by 0.68% to 13,184 units (SEC Form 4)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)